Table 3. Comparison of the incidence of nonvariceal upper GI bleeding (stratified by age).

Age	Days after infection	Dengue cohort		Nondengue cohort		Crude HR (95% CI)	P-value	Adjusted HR* (95% CI)	P-value	Adjusted SHR† (95% CI)	P-value
		No. of events	Incidence rate (per 1000 person-months)	No. of events	Incidence rate (per 1000 person-months)
≤ 50	≤ 30	67	8.82	3	0.10	89.64 (28.20–284.92)	< 0.0001	85.42 (26.83–271.93)	< 0.0001	85.41 (26.96–270.61)	< 0.0001
	> 30	41	0.05	178	0.06	0.92 (0.66–1.29)	0.630	0.85 (0.61–1.20)	0.360	0.87 (0.61–1.22)	0.409
	31–365	5	0.06	8	0.02	2.50 (0.82–7.65)	0.108	2.05 (0.66–6.43)	0.217	2.05 (0.68–6.12)	0.200
	> 365	36	0.05	170	0.06	0.85 (0.59–1.21)	0.360	0.77 (0.54–1.11)	0.168	0.79 (0.55–1.14)	0.199
51–64	≤ 30	72	20.62	4	0.28	72.72 (26.57–199.03)	< 0.0001	73.68 (26.86–202.06)	< 0.0001	73.59 (26.83–201.84)	< 0.0001
	> 30	92	0.25	332	0.23	1.11 (0.88–1.40)	0.386	1.02 (0.81–1.29)	0.865	1.04 (0.82–1.32)	0.725
	31–365	8	0.20	36	0.23	0.89 (0.42–1.92)	0.772	0.86 (0.40–1.87)	0.707	0.87 (0.40–1.88)	0.716
	> 365	84	0.26	296	0.23	1.13 (0.89–1.44)	0.313	1.04 (0.81–1.32)	0.772	1.06 (0.83–1.36)	0.657
≥ 65	≤ 30	56	31.27	7	0.94	32.53 (14.83–71.36)	< 0.0001	31.78 (14.43–70.01)	< 0.0001	31.72 (14.29–70.41)	< 0.0001
	> 30	114	0.71	429	0.67	1.06 (0.86–1.30)	0.596	0.98 (0.80–1.21)	0.881	1.02 (0.83–1.26)	0.829
	31–365	10	0.50	66	0.81	0.61 (0.32–1.19)	0.148	0.60 (0.31–1.17)	0.134	0.60 (0.31–1.19)	0.144
	> 365	104	0.73	363	0.64	1.14 (0.91–1.41)	0.248	1.05 (0.85–1.31)	0.646	1.09 (0.87–1.35)	0.454

Adjusted HR*: Hazard ratio adjusted for age, sex, area of residence, comorbidities, and medications listed in Table 1.

Adjusted SHR† Subdistribution hazard ratio adjusted for age, sex, area of residence, comorbidities, and medications listed in Table 1.